Roivant President Eric Venker sells about $7 million in shares under trading plan
Roivant Sciences President Eric Venker sold 200,000 of the biopharma company's common shares for roughly $7 million, according to a Form 4 filing.
The sales took place on Oct. 20 in two blocks: 185,856 shares at a weighted-average price of $35.09 and 14,144 shares at a weighted-average price of $35.42. Together they come to about $7.02 million based on the reported prices.
The filing lists Venker's title as President and Immunovant CEO. It said the sales were made under a Rule 10b5-1 trading plan adopted on June 30, 2026.
Still a large holder
After the trades, Venker directly owned 1,399,154 Roivant common shares, the Form 4 shows. The filing reported no purchases.
Individual sale prices ranged from $34.38 to $35.51 a share, according to the filing's footnotes.
By the numbers
- Shares sold: 200,000
- Approximate value: $7.02 million
- Weighted-average prices: $35.09 and $35.42
- Shares held directly afterward: 1,399,154
- Plan adopted: June 30, 2026
Sources
- Roivant Sciences Ltd., Form 4 for Eric Venker filed Oct. 22, 2026, accession 0001635088-26-000116
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.
Continue your research with IDD Pro
Get full access to IDD's market intelligence.